This year, Alzheimer’s Association International Conference (AAIC) 2020, while virtual, was an exciting and highly engaging event for Simoa® technology and ready-to-use Simoa® assay kits.
Though the 2019 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference has passed, Quanterix is not slowing down and working hard to continue the
Alzheimer’s disease is a dangerous and ultimately fatal form of dementia, and according to recent data from the Centers for Disease Control (CDC), Alzheimer’s is the sixth leading cause of death in the United States, accounting for 3.6% of all deaths. What’s more, the CDC also reports that the number of deaths from Alzheimer’s disease in the United States has risen by 55% in the last 15 years alone. With the numbers on the rise, it’s more important than ever that we continue to accelerate research to advance treatment options for this and other progressive neurodegenerative diseases.
When we think of the letters N-F-L, our minds are drawn to football and the National Football League. However, NfL, or ineurofilament light chain as the non-abbreviated name, is also a powerful protein that has shown promise for the early detection and diagnosis of brain injuries, as well as several neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease.